GlassScriptPhysician profile
James R Morris
NPI 1902904501
$866.14
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $35.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $304.34 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $150.79 | 2019 | |
| Scilex Pharmaceuticals INC. | $69.96 | 2019 | |
| Lilly USA, LLC | $59.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.38 | 2019-2020 | |
| Pfizer INC. | $39.89 | 2019 | |
| Pacira Therapeutics, INC. | $33.76 | 2019 | |
| Collegium Pharmaceutical, INC. | $26.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.52 | 2019 | |
| Allergan, INC. | $24.24 | 2019 | |
| Assertio Therapeutics, INC. | $23.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.98 | 2019 | |
| Boston Scientific Corporation | $14.82 | 2019 | |
| Indivior INC. | $11.49 | 2019 | |
| Si-Bone, INC. | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.